Affiliation:
1. Academic Affairs, Cedars-Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048
Abstract
Abstract
Leukemia-inhibitory factor (LIF) is a pleiotropic cytokine expressed by multiple tissue types. The LIF receptor shares a common gp130 receptor subunit with the IL-6 cytokine superfamily. LIF signaling is mediated mainly by JAK-STAT (janus-kinase-signal transducer and activator of transcription) pathways and is abrogated by the SOCS (suppressor-of cytokine signaling) and PIAS (protein inhibitors of activated STAT) proteins. In addition to classic hematopoietic and neuronal actions, LIF plays a critical role in several endocrine functions including the utero-placental unit, the hypothalamo-pituitary-adrenal axis, bone cell metabolism, energy homeostasis, and hormonally responsive tumors. This paper reviews recent advances in our understanding of molecular mechanisms regulating LIF expression and action and also provides a systemic overview of LIF-mediated endocrine regulation. Local and systemic LIF serve to integrate multiple developmental and functional cell signals, culminating in maintaining appropriate hormonal and metabolic homeostasis. LIF thus functions as a critical molecular interface between the neuroimmune and endocrine systems.
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference447 articles.
1. LIF: not just a leukemia inhibitory factor.;Kurzrock;Endocr Rev,1991
2. Interleukin 6 and its receptor: ten years later.;Hirano;Int Rev Immunol,1998
3. GP130 and the interleukin-6 family of cytokines.;Taga;Annu Rev Immunol,1997
4. gp130 And the IL-6 family of cytokines: signaling mechanisms and thrombopoietic activities.;Nakashima;Semin Hematol,1998
5. Leukemia inhibitory factor: part of a large ingathering family.;Taupin;Int Rev Immunol,1998
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献